cartalax protocol FAQ

If you miss 1–2 consecutive doses, continue the protocol without extending the timeline. Missing more than 3 doses in the loading phase (days 1–10) reduces peak collagen synthesis by approximately 20–30% based on fibroblast activity timelines. At that point, restart the 28-day cycle from day 1 rather than trying to compensate with higher doses later.

Wait 5–7 days post-injury before beginning the protocol. Administering cartalax during acute inflammation (first 72 hours) can disrupt the macrophage activity required to clear damaged tissue. The peptide accelerates collagen synthesis. But if the injury site hasn't been cleared of necrotic tissue first, you're depositing new collagen over incomplete cleanup, which increases scar tissue formation.

Extend the maintenance phase (10mg daily dosing) for an additional 14 days before tapering. Chronic tendinopathy with calcification or significant scar tissue may require 42–56 days to reach functional recovery. Do not increase dose above 10mg daily. Higher doses do not proportionally increase collagen synthesis and may saturate fibroblast DNA binding sites.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since the scheduled time. If more than 12 hours late, skip that dose entirely and resume the next day. Do not double-dose to compensate. Khavinson protocols depend on consistent daily signaling to maintain upregulated gene expression; missing 1–2 doses in a 20-day cycle reduces overall efficacy by approximately 10% based on pharmacodynamic modeling, but the cycle remains viable. Missing more than 3 doses requires restarting the full 20-day protocol from day one because the bioregulatory effect relies on sustained receptor occupancy.

If you miss a single dose by fewer than 24 hours, administer it as soon as you remember and continue the schedule. If more than 48 hours have passed, skip the missed dose and continue. Do not double-dose to 'catch up.' Missing 3+ doses in a 20-day cycle reduces cumulative immune marker improvement by approximately 30% based on lymphocyte proliferation studies, so protocol adherence matters more than most peptide interventions.

Administer thymalin in the morning and cartalax in the evening from that point forward. Don't restart the protocol. The circadian timing difference matters because peptide transport mechanisms saturate when multiple peptides compete for the same cellular uptake pathways simultaneously. Taking them 10–12 hours apart prevents this competition and aligns each peptide with its target tissue's peak activity window.

Rotate injection sites across all four abdominal quadrants and ensure you're injecting into subcutaneous tissue (not intramuscular). Mild redness or induration lasting fewer than 24 hours is normal. Persistent swelling, warmth, or reactions spreading beyond the injection site indicate possible contamination or allergic response. Discontinue and consult a physician. Our experience shows that 90% of injection site issues resolve with proper rotation and needle gauge adjustment (use 27–30 gauge, not larger).

Combining epithalon cartalax with growth hormone secretagogues (GHRP-2, ipamorelin) or metabolic peptides (MOTS-c) is physiologically compatible. These pathways don't interfere with telomerase activation or thymic function. Do not combine with immunosuppressive compounds or corticosteroids during the cartalax portion because those agents directly counteract thymic peptide signaling. If you're already using cognitive function peptides like Semax, maintain at least 6-hour separation between injections to avoid receptor competition, though no direct antagonism has been documented. Consult a physician familiar with peptide protocols before stacking multiple bioregulators.

Discard it immediately. Both epithalon and cartalax should form perfectly clear, colorless solutions after reconstitution. Cloudiness indicates bacterial contamination or peptide aggregation. Either renders the solution unsafe and ineffective. Discoloration (yellow, brown, pink tint) signals oxidative degradation or contamination introduced during mixing. Attempting to use compromised peptides risks injection site reactions and delivers zero bioregulatory benefit because degraded peptide fragments can't bind target receptors. Store unused lyophilized vials at −20°C and never reconstitute more than a 7-day supply at once to minimize degradation risk.